BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
BELFAST - Fusion Antibodies plc (AIM:LON:FAB) announced Tuesday that the United States Patent and Trademark Office has granted its patent application for the OptiMAL antibody library technology.
The patent, titled "Antibody Library and Method," covers the library of antibodies currently screened within the company’s OptiMAL platform and the method for designing additional libraries. The technology is used for antibody discovery, affinity maturation, and sequence optimization.
This development follows the notice of allowance Fusion received from the U.S. Patent Office on May 22, 2025. The company is also pursuing patent applications for the OptiMAL Library in other territories including Europe, China and Japan.
With the U.S. patent secured, Fusion is planning a scientific presentation at the Antibody Engineering and Therapeutics conference in San Diego in December 2025, where it aims to commercially launch the OptiMAL platform.
"This confirms our unique approach to antibody library design and protects Fusion’s OptiMAL antibody library for years to come," said Richard Buick, Chief Scientific Officer of Fusion, according to the company’s press release.
Fusion Antibodies specializes in pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.